Limits of HLA mismatching in unrelated hematopoietic cell transplantation.

Blood
E W PetersdorfJohn A Hansen

Abstract

HLA matching between the donor and recipient improves the success of unrelated hematopoietic cell transplantation (HCT). Matched donors are available for only a minority of patients. Further information is needed to evaluate the limits of HLA mismatching. We examined the association of mortality with HLA-A, -B, -C, -DRB1, and -DQB1 mismatching in 948 patients who received a T-replete unrelated HCT for treatment of a marrow disorder. A single HLA allele or antigen mismatch was associated with increased mortality among patients with chronic myeloid leukemia (CML) within 2 years after diagnosis compared to patients with no HLA mismatch, but not among those with more advanced malignancy. In particular, a single HLA-C mismatch conferred increased risk of mortality compared to matches. There was a suggestion for increased mortality with multiple mismatches involving HLA-DQB1 compared to multiple mismatches not involving HLA-DQB1. Donors with a single HLA allele or antigen mismatch may be used for HCT when a fully matched donor is not available for patients with diseases that do not permit time for a lengthy search. Whenever possible, HLA-C mismatches should be avoided for patients with early stage CML, and HLA-DQB1 mismatches should ...Continue Reading

References

Dec 15, 1977·The New England Journal of Medicine·R J O'ReillyR A Good
Jan 26, 1989·The New England Journal of Medicine·C AnasettiE Mickelson
Sep 4, 1980·The New England Journal of Medicine·J A HansenE R Giblett
Mar 4, 1993·The New England Journal of Medicine·N A KernanJ McCullough
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·E W PetersdorfJ A Hansen
Jul 1, 1997·Current Opinion in Hematology·J M Goldman
Apr 2, 1998·The New England Journal of Medicine·J A HansenC Anasetti
Dec 26, 2001·The New England Journal of Medicine·E W PetersdorfC Anasetti
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Mar 3, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Elena G ChioreanJeffrey S Miller

❮ Previous
Next ❯

Citations

Sep 13, 2011·Cancer Chemotherapy and Pharmacology·Jeannine S McCunePaul V O'Donnell
Jun 7, 2005·Human Immunology·Pierre-Antoine GourraudAnne Cambon-Thomsen
Jul 24, 2008·Bone Marrow Transplantation·E LaninoUNKNOWN Eurocord
Mar 28, 2006·Bone Marrow Transplantation·Y ChalandonUNKNOWN Swiss National Donor Registry
Dec 12, 2007·Bone Marrow Transplantation·A H SchmidtC Rutt
Apr 23, 2005·Seminars in Hematology·Eliane GluckmanVanderson Rocha
Apr 23, 2005·Seminars in Hematology·Effie W Petersdorf, Mari Malkki
Apr 23, 2005·Seminars in Hematology·Katharine C Hsu, Bo Dupont
Aug 31, 2012·The New England Journal of Medicine·Jeffrey M VenstromKatharine C Hsu
Nov 17, 2010·The Journal of Experimental Medicine·Jörn C AlbringKenneth M Murphy
Nov 19, 2004·Current Opinion in Hematology·Effie W Petersdorf
Oct 4, 2008·Current Opinion in Hematology·Effie W Petersdorf, John A Hansen
Nov 3, 2012·Bone Marrow Research·Neema P MayorSteven G E Marsh
Oct 26, 2012·Bone Marrow Research·Catherine Stavropoulos-GiokasAndreas Papassavas
Jun 7, 2012·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Christian GabrielJohannes Pröll
Jan 9, 2009·BMC Health Services Research·Martina WannerAlexander H Schmidt
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mukta AroraEffie W Petersdorf
Mar 24, 2007·PLoS Medicine·Effie W PetersdorfZhen Guo
Jan 28, 2014·BMC Genomics·Vinzenz LangeAlexander H Schmidt
Oct 20, 2012·Bone Marrow Research·Meerim Park, Jong Jin Seo
Nov 6, 2007·Bone Marrow Transplantation·J J van Rood, M Oudshoorn
Sep 28, 2010·Expert Review of Hematology·Boglarka GyurkoczaRainer F Storb
Mar 24, 2016·Seminars in Hematology·Henning Sebastian Schäfer, Jürgen Finke
Oct 11, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Florent DelbosSébastien Maury

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.